Hualan Vaccine
Hualan Vaccine Henan province
Hualan Bio Vaccine, founded in 2005 and headquartered in Xinxiang, Henan province, is a modern vaccine manufacturer, mainly developing and producing human bacterial vaccines, viral vaccines, genetic engineering vaccines and other high-tech products. Its main competitors include Changsheng and GDK
F-star to be acquired by China biopharmaceutical with USD 161million
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Jun 24, 2022 12:13 PM
East China medicine "liraglutide" goes to sea
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Research
Real Estate, Consumer Discretionary, IndustrialsTech for Global, Globalization Footprints of the Established and the New
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Yanye new crown drug 3CL protein inhibitor has been suspended approval
RNA Biotech Therorna Bags Over CNY 280 Mn in Series A Financing Round
Therorna, specialized in the development of cutting-edge circular RNA technology-based vaccines and therapies, will accelerate the development of a new broad-spectrum COVID-19 vaccine and other product pipelines with the fresh proceeds.
Jun 23, 2022 03:45 PM
Sanofi Greater China will be headed by Shi Wang, and Henting he will become the global head of the digital business unit
AI-driven pharmaceutics Company Helixon Raise CNY 500 Mn in Series A Round
As one of the key players in computational biology, Helixon received recognition from the capital market for its innovation in machine learning algorithms and data acquisition technologies which reconstruct the drug development process and improve the efficiency of new drug development.
Jun 22, 2022 06:13 PM
Hualan biology: it is actively applying to relevant departments for the construction of a new plasma collection station